4.7 Article

Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 205, Issue -, Pages S391-S398

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis199

Keywords

-

Funding

  1. National Insitute of Allergy and Infectious Diseases, National Insitutes of Health [HRO1 AI093520]
  2. Harvard Center for AIDS Research
  3. Bristol Myers Squibb
  4. Gilead
  5. ViiV Healthcare
  6. EMD-Serono
  7. BMS
  8. Tibotec
  9. Merck
  10. GSK

Ask authors/readers for more resources

Osteoporosis is common in human immunodeficiency virus (HIV)-infected persons. The etiology of osteoporosis in HIV-infected patients is likely multifactorial, involving traditional risk factors such as low body weight, hypogonadism, and smoking, as well as direct effects of chronic HIV infection and antiretroviral therapy. Emerging evidence suggests that the increasing prevalence of osteoporosis in HIV-infected persons translates into a higher risk of fracture, likely leading to excess morbidity and mortality as the HIV-infected population ages. This review addresses the epidemiology of osteoporosis, discusses the causes of low bone mineral density in HIV-infected persons, including the impact of specific antiretroviral therapies, and offers recommendations on screening and treating vitamin D deficiency and osteoporosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available